InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.004 -0.002 (-27.27%)+
Announcement
Release
19 Aug 2026 5:24PM
Price at Release
$0.006
Full Release
download
Summary
Percheron Therapeutics Limited's Annual Report and Appendix 4E for the financial year ended 30 June 2026 outlines the company's financial performance and condition. The report reveals a net loss of $4,791,745, a significant decrease from the previous year's loss of $14,921,913. The issued capital decreased to $63,417,726 from $112,048,298, reflecting the issuance and cancellation of share capital. The company's cash flow from operations also saw a decrease, with net cash used in operating activities recorded at $4,961,105. Significant focus was placed on research and development, with expenses amounting to $2,087,558. Percheron maintained its strategy of developing therapeutic solutions, with a notable license agreement with Hummingbird Bioscience. The financial statements highlight the company's ongoing efforts in research and the need for continued financial resource management.
Key Points
  • Net loss of $4,791,745 for the year ended 30 June 2026.
  • Issued capital decreased significantly due to capital transactions.
  • Net cash used in operating activities was $4,961,105.
  • Research and development expenses totaled $2,087,558.
  • Significant agreement with Hummingbird Bioscience for HMBD-002.
  • Continued focus on developing therapeutic solutions.
  • Shares listed on ASX, Frankfurt, and US OTC Markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.